Impact of a system to assist in clinical decision-making in primary healthcare in Catalonia: prescription Self Audit

Table 4 Top 10 prescribed duplicate groups in 2017 and 2018, including June–December variations

Duplicate group*	June 2017	Dec 2017	Variation	Percentage (%)	June 2018	Dec 2018	Variation	Percentage (%)
Renin-angiotensin system inhibitors	2458	2141	–317	–13	2107	1939	–168	–9
Anti-inflammatories	2154	1880	–274	–13	2203	1969	–234	–12
Long-acting benzodiazepines	2032	1911	–121	–6	2064	1854	–210	–11
Inhaled glucocorticoids	1551	1616	65	4	1583	1771	188	11
Alpha adrenergic antagonists	1273	1299	26	2	1337	1346	9	1
Gastric protectors	1425	1162	–263	–18	1364	1276	–88	–7
Other anti-depressants I	1467	1389	–78	–5	1562	1702	140	8
Urinary antispasmodic agents	1655	1547	–108	–7	1876	2020	144	7
Thiazide diuretics	964	823	–141	–15	2085	1595	–490	–31
Paracetamol (analgesic)	545	668	123	23	523	570	47	8

For technical reasons, the April data were not recorded at the level of detail required for the duplication group and so they have not been included in the table. The data were analysed in June and December, at which points they met the level of quality and detail required for analysis
*For each duplicate group, all available active prescription data are shown, which coincide with the evaluation points

ISSN: 1472-6947